- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06851832
Ensaio clínico do Herpes Zoster vacina recombinante (célula CHO) em população chinesa saudável com 40 anos ou mais
Um ensaio clínico de fase I/II com design randomizado, cego e controlado para avaliar a segurança e a imunogenicidade do Herpes Zoster vacina recombinante (célula CHO) em populações saudáveis com 40 anos ou mais pós -vacinação
The objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Henan
-
Xuchang, Henan, China
- Xiangcheng County Center for Disease Control and Prevention
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or female participants aged 40 years or older at the time of enrollment.
- Voluntarily agrees to participate in the trial, fully understands, and signs the informed consent form.
- Able to attend all scheduled follow-ups and comply with the clinical trial protocol requirements to complete the trial.
- Female participants must meet the following criteria:1)Surgically sterilized or postmenopausal for ≥2 years, or women of childbearing potential (not menopausal or menopausal <2 years) with a negative pregnancy test and willing to use effective physical contraception (e.g., condoms, intrauterine device) from enrollment until 6 months after full immunization. 2)Agree not to breastfeed from enrollment until 6 months after full immunization.
- Axillary temperature ≤37.0°C.
Exclusion Criteria:
a Exclusion criteria for the first dose:
- A history of herpes zoster.
- A history of varicella or herpes zoster vaccination.
- Close contact with a varicella/herpes zoster patient within the past year.
- Received immunoglobulin and/or any blood products within 3 months before vaccination.
- Received immunosuppressive treatment within 3 months prior to vaccination (e.g., systemic corticosteroids for ≥14 days, at a dose ≥2 mg/kg/day or ≥20 mg/day of prednisone, or an equivalent dose of prednisone) (excluding inhaled, intra-articular, and topical steroids).
- A history of severe allergic reactions to any vaccine or medication (e.g., anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reactions, severe urticaria, etc.), or a family history of severe allergies.
- Immunocompromised or diagnosed with congenital or acquired immune deficiency diseases, or infected with Human Immunodeficiency Virus (HIV).
- A history of seizures, epilepsy, encephalopathy (such as congenital brain malformation, brain trauma, brain tumors, cerebral hemorrhage, cerebral infarction [except for infarction without sequelae or lacunar infarction], brain infections, or brain damage caused by chemical drug poisoning), or psychiatric disorders, or a family history of psychiatric disorders; or other serious neurological diseases.
- Inadequate time interval between vaccination and other vaccines (e.g., inactivated or recombinant subunit vaccines within 14 days prior to vaccination, live attenuated vaccines, viral vector vaccines, or mRNA vaccines within 28 days prior to vaccination).
- Acute illness or an acute exacerbation of a chronic disease within 3 days prior to vaccination, or use of antipyretic, analgesic, or antihistamine medications within 3 days prior to vaccination.
- Suffering from severe infectious skin diseases.
- Ongoing or long-term alcohol and/or drug abuse history (Note: for the past three months, males drinking more than 14 standard drinks per week, females more than 7 standard drinks per week. One standard drink contains 14g of alcohol, equivalent to 360mL of beer, 45mL of liquor at 40% alcohol, or 150mL of wine. Drug abuse refers to the repeated or excessive use of drugs with dependence potential unrelated to recognized medical needs, for non-medical purposes).
- A history of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection.
- Severe liver or kidney disease, complications from diabetes, severe cardiovascular diseases, or uncontrolled hypertension despite medication.
- Asplenia or functional asplenia, or any condition leading to splenectomy.
- Abnormal laboratory test results before the first dose, deemed clinically significant by the investigator (only applicable to Phase I).
- Currently participating in other experimental or unregistered clinical trials for products (drugs, vaccines, or devices), or planning to participate in another clinical trial before the end of this trial.
- A history of hematologic or lymphatic system diseases, such as unexplained lymphadenopathy or hematolymphatic lymphoma.
- A history of diagnosed potential immune-mediated diseases, autoimmune diseases, or Guillain-Barré syndrome.
- Any other condition deemed by the investigator to be unsuitable for participation in this clinical trial.
a Exclusion criteria for the second dose:
- Positive urine pregnancy test.
- Grade 4 adverse events related to vaccination.
- Severe allergic reactions occurring after vaccination.
- New findings or newly occurring conditions that meet the exclusion criteria after the first dose, with the investigator determining whether to terminate the trial vaccine administration.
- Other situations assessed by the investigator as requiring termination of vaccination.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Recombinant zoster Vaccine (CHO cell) (low adjuvant)
It is used for vaccination of experimental vaccine group A subjects in phase I and II clinical trials |
The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 50 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose. |
|
Experimental: Recombinant zoster Vaccine (CHO cell)
It is used for vaccination of experimental vaccine group B subjects of phase I clinical trial , experimental vaccine group B1 and B2 subjects of phase II clinical trial |
|
|
Comparador Ativo: Zoster Vaccine, Live
It is used for vaccination of positive control group A1 and A2 subjects in phase Ⅱ clinical trial |
The dosage for each administration is 0.5 mL, containing not less than 4.3 lg PFU of varicella-zoster live virus, administered subcutaneously at the attachment site of the lower edge of the deltoid muscle on the outer side of the upper arm. A total of one dose will be given. To maintain blinding, the positive control group A1 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 30. The positive control group A2 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 60. |
|
Comparador Ativo: Recombinant Zoster Vaccine (CHO cell)
It is used for vaccination of positive control group B subjects in phase Ⅱ clinical trial |
|
|
Comparador de Placebo: Recombinant Zoster Vaccine (CHO cell) (Adjuvant control)
It is used for vaccination of adjuvant control group subjects in phase Ⅰ clinical trial |
The dosage for each administration is 0.5 mL, containing 0.25 mL of MF59 and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose. |
|
Comparador de Placebo: normal saline
Used in phase Ⅰ clinical trial; To maintain blinding, positive control group A1 and positive control group A2 received placebo on day 0 (for phase II clinical trial). |
The dosage for each administration is 0.5 mL, containing 0.5 mL of NaCl solution, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose (applicable to Phase I clinical trial). To maintain blinding, subjects in the positive control A1 and positive control A2 groups will receive a placebo on Day 0 (applicable to Phase II clinical trial). |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
A incidência de anormalidades laboratoriais (incluindo bioquímica sanguínea, rotina sanguínea, rotina de urina e eletrocardiograma) no dia 3 após cada dose de vacina.
Prazo: No dia 3 após cada dose de vacina. (Aplicável apenas à fase I)
|
No dia 3 após cada dose de vacina. (Aplicável apenas à fase I)
|
|
|
A incidência de eventos adversos graves (SAEs) e eventos adversos de interesse especial (AESI) da vacinação da primeira dose a 12 meses após a imunização total.
Prazo: Desde a vacinação da primeira dose a 12 meses após a imunização total.
|
Desde a vacinação da primeira dose a 12 meses após a imunização total.
|
|
|
A incidência de eventos adversos locais e sistêmicos solicitados (EAs) dentro de 0 a 14 dias após cada dose da vacina.
Prazo: Dentro de 14 dias após cada dose de vacina.
|
Dentro de 14 dias após cada dose de vacina.
|
|
|
A incidência de eventos adversos não solicitados (EAs) dentro de 0 a 30 dias após cada dose de vacina.
Prazo: Dentro de 30 dias após cada dose de vacina.
|
Dentro de 30 dias após cada dose de vacina.
|
|
|
The cell-mediated immune response rate of CD4+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L) one month after full immunization.
Prazo: One month after full immunization.(Applicable to Phase Ⅱ only)
|
Detected using intracellular cytokine staining (ICS) by flow cytometry |
One month after full immunization.(Applicable to Phase Ⅱ only)
|
|
The GMC/GMT, seroconversion rate, and GMI of anti-gE antibodies and anti-VZV antibodies one month after full immunization.
Prazo: One month after full immunization.(Applicable to Phase Ⅱ only)
|
Detected using enzyme-linked immunosorbent assay (ELISA). |
One month after full immunization.(Applicable to Phase Ⅱ only)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The GMC/GMT, seroconversion rate, and GMI of anti-gE antibodies and anti-VZV antibodies at 6, 12, 24, and 36 months after full immunization.
Prazo: At 6, 12, 24, and 36 months after full immunization.(Applicable to Phase Ⅱ only)
|
Detected using enzyme-linked immunosorbent assay (ELISA) |
At 6, 12, 24, and 36 months after full immunization.(Applicable to Phase Ⅱ only)
|
|
The cell-mediated immune response rate of CD4+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L) before the second dose and at 6, 12, 24, and 36 months after full immunization.
Prazo: Before the second dose and at 6, 12, 24, and 36 months after full immunization(Applicable to Phase Ⅱ only)
|
Detected using intracellular cytokine staining (ICS) by flow cytometry |
Before the second dose and at 6, 12, 24, and 36 months after full immunization(Applicable to Phase Ⅱ only)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Zhiqiang Xie, Master, Henan Center for Disease Control and Prevention
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Infecção pelo Vírus Varicela Zoster
- Infecções
- Doenças Virais
- Infecções por vírus de DNA
- Infecções Herpesviridae
- Herpes Zóster
- Preparações farmacêuticas
- Soluções cristalóides
- Soluções isotônicas
- Soluções
- Produtos biológicos
- Misturas complexas
- Vacinas
- Vacinas virais
- Vacinas de herpesvírus
- Vacina de varicela
- Solução salina
- Vacina do herpes zoster
Outros números de identificação do estudo
- VZV-ZHSW-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .